Found: 3
Select item for more details and to access through your institution.
A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019, v. 5, n. 1, p. 20, doi. 10.1016/j.trci.2018.11.001
- By:
- Publication type:
- Article
A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1570, doi. 10.1016/j.jalz.2017.07.730
- By:
- Publication type:
- Article
A TWO-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF CT1812 IN HEALTHY VOLUNTEERS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1183, doi. 10.1016/j.jalz.2016.07.127
- By:
- Publication type:
- Article